A5016906085- PARP inhibition in cancer therapy
- Glioma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Chronic Lymphocytic Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Cancer therapeutics and mechanisms
- Osteoarthritis Treatment and Mechanisms
- Drug Transport and Resistance Mechanisms
- Elbow and Forearm Trauma Treatment
- Cancer, Hypoxia, and Metabolism
- Orthopedic Surgery and Rehabilitation
- DNA Repair Mechanisms
- Ovarian cancer diagnosis and treatment
- Cell death mechanisms and regulation
- Brain Metastases and Treatment
- Extracellular vesicles in disease
- Lung Cancer Research Studies
- Colorectal and Anal Carcinomas
- BRCA gene mutations in cancer
- Cancer Genomics and Diagnostics
- Neuroblastoma Research and Treatments
- Radiopharmaceutical Chemistry and Applications
AbbVie (United States)
2014-2024
Shanghai Jiao Tong University
2018-2024
Macquarie University
2024
Xihua University
2024
Shanghai Sixth People's Hospital
2018-2023
Shanghai Innovative Research Center of Traditional Chinese Medicine
2021-2023
Jiangxi University of Traditional Chinese Medicine
2023
Nanjing Medical University
2022-2023
Jiangsu Province Hospital
2022
Wuhan Children's Hospital
2021
BCL2 overexpression is a hallmark of chronic lymphocytic leukemia (CLL). The novel BH3 mimetic navitoclax (ABT-263) specifically inhibits and related proteins BCL-x(l) BCL-w, potently inducing apoptosis CLL cells in vitro. A phase I trial patients with was conducted to evaluate the safety, pharmacokinetics, biologic activity oral navitoclax.Twenty-nine relapsed or refractory received daily for 14 days (10, 110, 200, 250 mg/d; n = 15) 21 (125, 250, 300 14) each 21-day cycle. Dose escalation...
Resistance to chemotherapy-induced apoptosis represents a major obstacle cancer control. Overexpression of Bcl-2 is seen in multiple tumor types and targeting may provide therapeutic benefit. A phase I study navitoclax, novel inhibitor family proteins, was conducted evaluate safety, pharmacokinetics, preliminary efficacy patients with solid tumors.Patients enrolled intermittent dosing cohorts received navitoclax on day -3, followed by days 1 14 21-day cycle. Patients continuous 1-week...
Repairing peripheral nerve injury, especially long-range defects of thick nerves, is a great challenge in the clinic due to their limited regeneration capability. Most FDA-approved guidance conduits with large hollow lumen are only suitable for short lesions, and effects unsatisfactory repairing long gaps nerves. Multichannel have been shown offer better defects. However, existing approaches fabricating multichannel usually complicated time-consuming. Inspired by intelligent responsive...
Osteoarthritis (OA) is the most common disabling joint disease with no effective modifying drugs. Extracellular vesicles released by several types of mesenchymal stem cells could promote cartilage repair and ameliorate OA pathology in animal models, representing a novel therapeutic strategy. In this study, we demonstrated that extracellular derived from human umbilical cord (hUC-EVs) maintain chondrocyte homeostasis alleviate OA, further revealed molecular mechanism effect. miR-223, which...
Patients with recurrent glioblastoma (rGBM) have a poor prognosis. Epidermal growth factor receptor (EGFR) gene amplification is present in ~ 50% of glioblastomas (GBMs). Depatuxizumab mafodotin (depatux-m), formerly ABT-414, an antibody-drug conjugate that preferentially binds cells EGFR amplification, internalized and releases potent antimicrotubule agent, monomethyl auristatin F (MMAF). Here we report the safety, pharmacokinetics, efficacy depatux-m monotherapy at recommended Phase 2 dose...
The purpose of this study was to determine the maximum tolerated dose (MTD), recommended phase II (RPTD), safety, and pharmacokinetics ABT-414 plus radiation temozolomide in newly diagnosed glioblastoma. is a first-in-class, tumor-specific antibody-drug conjugate that preferentially targets tumors expressing overactive epidermal growth factor receptor (EGFR).
Patients with glioblastoma (GBM) have a dismal prognosis. Nearly all will relapse no clear standard of care for recurrent disease (rGBM). Approximately 50% patients tumors harboring epidermal growth factor receptor (EGFR) amplification. The antibody-drug conjugate depatuxizumab mafodotin (depatux-m) binds cells EGFR amplification, is internalized, and releases microtubule toxin, killing the cell. Here we report efficacy, safety pharmacokinetics (PK) depatux-m + temozolomide (TMZ) in...
Abstract Background Exosomes are extracellular vesicles of nano-structures and represent an emerging nano-scale acellular therapy in recent years. Tendon regeneration is a sophisticated process the field microsurgery due to its poor natural healing ability. To date, no successful long-term solution has been provided for tendon injuries. Functional recovery requires advanced treatment strategies. Human umbilical cord mesenchymal stem cell-derived exosomes (HUMSC-Exos) considered as promising...
Abstract Nanozymes are widely applied for treating various major diseases, including neurological diseases and tumors. However, the biodegradability of nanozymes remains a great challenge, which hinders their further clinical translation. Based on microenvironment osteoarthritis (OA), representative pH‐responsive biodegradable hollow‐structured manganese Prussian blue nanozyme (HMPBzyme) is designed treatment OA. HMPBzyme with good biodegradability, biocompatibility, multi‐enzyme activities...
Abstract The occurrence of osteoarthritis (OA) is highly associated with the inflammatory hypoxic microenvironment. Yet currently no attention has been paid to fabricating hypoxia‐responsive platforms for OA treatment. Herein, an injectable hydrogel microsphere system (HAM‐SA@HCQ) focusing on inflamed joint prepared methacrylate‐modified sulfonated azocalix[4]arene (SAC4A‐MA), methacrylated hyaluronic acid (HA‐MA), and dithiol‐terminated matrix metalloproteinase 13 (MMP‐13) sensitive peptide...
Hepatic disposition of 5 (and 6)-carboxy-2′,7′-dichlorofluorescein (CDF) and its diacetate promoiety (CDFDA) was studied in isolated perfused rat livers. Livers from Wistar wild-type multidrug resistance-associated protein (Mrp)2-deficient (TR<sup>−</sup>) rats were with CDF the presence or absence probenecid. Probenecid decreased recovery bile ∼4-fold livers (65 ± 8% versus 15 2% dose over 2 h). In TR<sup>−</sup> rats, not excreted into probenecid perfusate concentrations a...
Purpose: PARP plays an important role in DNA repair. Veliparib, a inhibitor, enhances the efficacy of platinum compounds and has been safely combined with carboplatin paclitaxel. The primary endpoint this phase II trial determined whether addition veliparib to paclitaxel improved progression-free survival (PFS) previously untreated patients advanced/metastatic non-small cell lung cancer.Experimental Design: Patients were randomized 2:1 either or placebo. Veliparib (120 mg) placebo was given...
We recently reported an acceptable safety and pharmacokinetic profile of depatuxizumab mafodotin (depatux-m), formerly called ABT-414, plus radiation temozolomide in newly diagnosed glioblastoma (arm A). The purpose this study was to evaluate the pharmacokinetics depatux-m, either combination with or recurrent B) as monotherapy C).In multicenter phase I dose escalation study, patients received depatux-m (0.5-1.5 mg/kg arm B, 1.25 C) every 2 weeks by intravenous infusion. Maximum tolerated...
Heterotopic ossification (HO) is one of the most intractable disorders following musculoskeletal injury and characterized by ectopic presence bone tissue in soft leading to severe loss function extremities. Recent studies have indicated that immune cell infiltration inflammation are involved aberrant formation. In this study, we found increased monocyte/macrophage mast accumulation during early HO progression. Macrophage depletion clodronate liposomes stabilization cromolyn sodium...
Previous studies have demonstrated that phenobarbital treatment impairs the biliary excretion of acetaminophen glucuronide (AG), although transport system(s) responsible for AG into bile has not been identified. Initial in rat canalicular liver plasma membrane vesicles indicated uptake was stimulated modestly by ATP, but potential, HCO(3)(-), or pH gradients. To examine role ATP-dependent transporter multidrug resistance-associated protein 2 (Mrp2)/canalicular multispecific organic anion...
4544 Background: BAY 43–9006 (BAY) is a Raf kinase and VEGFR inhibitor with effects on both tumor proliferation angiogenesis. This Phase II RDT determined the of growth in patients (pts) stable disease (SD) after 12 wks treatment. Methods: 202 pts advanced RCC (ECOG 1–2) entered 12-wk induction phase (BAY 400 mg po bid). Pts bidimensional measurements remaining within 25% baseline were then randomized (double-blind) to bid or placebo (Pb), progression-free rate [percentage SD response] at 24...
Objective Our objective was to learn whether genetic polymorphisms of metabolic enzymes or transport proteins provide a mechanistic understanding the in vivo disposition atrasentan, selective endothelin A receptor antagonist. Methods Atrasentan uptake measured HeLa cells transfected express major alleles organic anion transporting polypeptide 1B1 (OATP1B1). The results were used classify individuals as extensive, intermediate, poor OATP1B1 transporters according their SLCO1B1 genotypes....